Vol 15, No 1 (2022)
Guidelines / Expert consensus
Published online: 2022-03-31

open access

Page views 5288
Article views/downloads 736
Get Citation

Connect on Social Media

Connect on Social Media

The Polish Society for Pediatric Nephrology (PTNFD) recommendations on the management of children with nephrotic syndrome

Maria Szczepańska1, Irena Bałasz-Chmielewska2, Ryszard Grenda3, Kinga Musiał4, Iwona Ogarek5, Małgorzata Pańczyk-Tomaszewska6, Jacek Zachwieja7, Aleksandra Żurowska2
DOI: 10.5603/RDTF.2022.0001
Renal Disease and Transplantation Forum 2022;15(1):36-57.

Abstract

On behalf of the Polish Society for Pediatric Nephrology, a group of experts has upgraded the previously announced recommendations* on the management of children with nephrotic syndrome. Recommendations are based on the published European and American guidelines, the results of reliable trials and meta-analyses, as well as local experience. They should be regarded as advisory for pediatricians in their personal experience-driven choice of the optimal available strategy for the diagnostics and treatment of individual pediatric NS patients. The recommendations will be re-updated by the Society in the forthcoming years to account for the continued rapid progress of clinical research and knowledge in the field of glomerulonephritis.  

Article available in PDF format

View PDF Download PDF file

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis. Kidney Int. ; 2(Suppl. 2012): 139–274.
  2. Rovin BH, Caster DJ, Cattran DC, et al. Conference Participants. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019; 95(2): 281–295.
  3. Beck L, Bomback AS, Choi MJ, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis. 2013; 62(3): 403–441.
  4. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis. Kidney Int. 2020; 2: 153–176.
  5. Lombel RM, Gipson DS, Hodson EM, et al. Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol. 2013; 28(3): 415–426.
  6. Lombel RM, Gipson DS, Hodson EM, et al. Kidney Disease: Improving Global Outcomes, Kidney Disease: Improving Global Outcomes. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr Nephrol. 2013; 28(3): 409–414.
  7. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978; 13(2): 159–165.
  8. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003; 362(9384): 629–639.
  9. Bierzynska A, Soderquest K, Koziell A. Genes and podocytes - new insights into mechanisms of podocytopathy. Front Endocrinol (Lausanne). 2014; 5: 226.
  10. Varner JD, Chryst-Stangl M, Esezobor CI, et al. Genetic testing for steroid-resistant-nephrotic syndrome in an outbred population. Front Pediatr. 2018; 6: 307.
  11. Trautmann A, Bodria M, Ozaltin F, et al. PodoNet Consortium. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol. 2015; 10(4): 592–600.
  12. Abramowicz M, Barnett HL, Edelmann CM, et al. Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children. The Lancet. 1970; 295(7654): 959–961.
  13. Feber J, Al-Matrafi J, Farhadi E, et al. Prednisone dosing per body weight or body surface area in children with nephrotic syndrome: is it equivalent? Pediatr Nephrol. 2009; 24(5): 1027–1031.
  14. Saadeh SA, Baracco R, Jain A, et al. Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference? Pediatr Nephrol. 2011; 26(12): 2167–2171.
  15. Ekka BK, Bagga A, Srivastava RN. Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr Nephrol. 1997; 11(5): 597–599.
  16. Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2007(4): CD001533.
  17. Ueda N, Chihara M, Kawaguchi S, et al. Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. J Pediatr. 1988; 112(1): 122–126.
  18. Ehrich JH, Brodehl J, Brodehl J, et al. The treatment of minimal change nephrotic syndrome (lipoid nephrosis): cooperative studies of the Arbeitsgemeinschaft für Pädiatrische Nephrologie (APN). Klin Padiatr. 1982; 194(3): 162–165.
  19. Ksiazek J, Wyszyńska T. Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Acta Paediatr. 1995; 84(8): 889–893.
  20. Bagga A, Hari P, Srivastava RN. Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome. Pediatr Nephrol. 1999; 13(9): 824–827.
  21. Hiraoka M, Tsukahara H, Matsubara K, et al. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. American Journal of Kidney Diseases. 2003; 41(6): 1155–1162.
  22. Lombel RM, Gipson DS, Hodson EM, et al. Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol. 2013; 28(3): 415–426.
  23. Ziółkowska H, Bałasz-Chmielewska I, Grenda R, et al. Zalecenia Polskiego Towarzystwa Nefrologii Dziecięcej (PTNFD) dotyczące postępowania z dzieckiem z zespołem nerczycowym. Forum Nefrol. 2015; 8: 238–256.
  24. Teeninga N, Kist-van Holthe JE, van Rijswijk N, et al. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol. 2013; 24(1): 149–159.
  25. Sinha A, Saha A, Kumar M, et al. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int. 2015; 87(1): 217–224.
  26. Yoshikawa N, Nakanishi K, Sako M, et al. Japanese Study Group of Kidney Disease in Children. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int. 2015; 87(1): 225–232.
  27. Hahn D, Hodson EM, Willis NS, et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015(3): CD001533.
  28. Hodson EM, Hahn D, Craig JC. Corticosteroids for the initial episode of steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2015; 30(7): 1043–1046.
  29. Couderc A, Bérard E, Guigonis V, et al. [Treatments of steroid-dependent nephrotic syndrome in children]. Arch Pediatr. 2017; 24(12): 1312–1320.
  30. Pasini A, Benetti E, Conti G, et al. The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse. Ital J Pediatr. 2017; 43(1): 41.
  31. Ramachandran R, Jha V. Integration with Kidney Disease Improving Global Outcomes (KDIGO). Glomerulonephritis. 2019: 87–95.
  32. Webb NJa, Woolley RL, Lambe T, et al. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT. Health Technol Assess. 2019; 23(26): 1–108.
  33. Hahn D, Hodson EM, Willis NS, et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015; 30(3): CD001533–1046.
  34. Nephrotic syndrome in children: A randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. The Journal of Pediatrics. 1979; 95(2): 228–233.
  35. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis. Kidney Int. Suppl. 2020; 2: 153–176.
  36. Alternate-day prednisone is more effective than intermittent prednisone in frequently relapsing nephrotic syndrome. A report of "Arbeitsgemeinschaft für Pädiatrische Nephrologie. Eur J Pediatr. 1981; 135(3): 229–237.
  37. MacDonald NE, Wolfish N, McLaine P, et al. Role of respiratory viruses in exacerbations of primary nephrotic syndrome. J Pediatr. 1986; 108(3): 378–382.
  38. Mattoo TK, Mahmoud MA. Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome. Nephron. 2000; 85(4): 343–345.
  39. Abeyagunawardena AS, Thalgahagoda RS, Dissanayake PV, et al. Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome. Pediatr Nephrol. 2017; 32(8): 1377–1382.
  40. Gulati A, Sinha A, Sreenivas V, et al. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011; 6(1): 63–69.
  41. Webb N, Frew E, Brettell E, et al. Short course daily prednisolone therapy during an upper respiratory tract infection in children with relapsing steroid-sensitive nephrotic syndrome (PREDNOS 2): protocol for a randomised controlled trial. Trials. 2014; 15(1).
  42. Lombel RM, Gipson DS, Hodson EM, et al. Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol. 2013; 28(3): 415–426.
  43. Nakanishi K, Iijima K, Ishikura K, et al. Japanese Study Group of Renal Disease in Children. Two-year outcome of the ISKDC regimen and frequent-relapsing risk in children with idiopathic nephrotic syndrome. Clin J Am Soc Nephrol. 2013; 8(5): 756–762.
  44. Hodson EM, Knight JF, Willis NS, et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2000(4): CD001533.
  45. Gulati A, Sinha A, Sreenivas V, et al. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011; 6(1): 63–69.
  46. Webb NJ, Frew E, Brettell EA, et al. for PREDNOS 2 study group. Trials. 2014; 15: 147.
  47. Hahn D, Hodson EM, Willis NS, et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015; 30(3): CD001533–1046.
  48. Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev. 2008(1): CD002290.
  49. Ishikura K, Ikeda M, Hattori S, et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 2008; 73(10): 1167–1173.
  50. Niaudet P. Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol. 1992; 6(1): 1–3.
  51. Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant. 1993; 8(12): 1326–1332.
  52. Cammas B, Harambat J, Bertholet-Thomas A, et al. Long-effects of cyclophosphamide therapy in steroid-dependent and frequently relapsing idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2011; 26: 178–184.
  53. Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol. 2001; 16(3): 271–282.
  54. Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol. 2008; 23(11): 2013–2020.
  55. Gellerman J, Querfeld U. Frequently relapsing steroid-sensitive nephrotic syndrome (SSNS) in children and adolescents: treatment with mycophenolate mofetil (MMF) vs cyclosporine (CsA). Pediatr Nephrol. 2011; 26: 1579–1582.
  56. Fujinaga S, Ohtomo Y, Umino D, et al. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol. 2007; 22(1): 71–76.
  57. Kirpalani A, Rothfels L, Sharma AP, et al. Nephrotic state substantially enhances apparent mycophenolic acid clearance
. Clin Nephrol. 2019; 91(3): 162–171.
  58. Hackl Á, Cseprekál O, Gessner M, et al. Mycophenolate mofetil therapy in children with idiopathic nephrotic syndrome: does therapeutic drug monitoring make a difference? Ther Drug Monit. 2016; 38(2): 274–279.
  59. Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008; 23(8): 1269–1279.
  60. Ravani P, Rossi R, Bonanni A, et al. Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol. 2015; 26(9): 2259–2266.
  61. Sellier-Leclerc AL, Baudouin V, Kwon T, et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery. Nephrol Dial Transplant. 2012; 27(3): 1083–1089.
  62. Lombel RM, Gipson DS, Hodson EM, et al. Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol. 2013; 28(3): 415–426.
  63. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis. Kidney Int. Suppl. 2020; 2: 153–176.
  64. Chan EYH, Tullus K. Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen. Pediatr Nephrol. 2021; 36(6): 1397–1405.
  65. Larkins NG, Liu ID, Willis NS, et al. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev. 2020; 4: CD002290.
  66. Sadowski CE, Lovric S, Ashraf S, et al. SRNS Study Group. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2015; 26(6): 1279–1289.
  67. Santín S, Bullich G, Tazón-Vega B, et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol. 2011; 6(5): 1139–1148.
  68. Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993; 43(6): 1377–1384.
  69. Bagga A, Mudigoudar BD, Hari P, et al. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2004; 19(1): 45–50.
  70. Trautmann A, Bodria M, Ozaltin F, et al. PodoNet Consortium. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol. 2015; 10(4): 592–600.
  71. Shenoy M, Plant ND, Lewis MA, et al. Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome. Pediatr Nephrol. 2010; 25(5): 899–903.
  72. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 1996; 7(1): 56–63.
  73. Choudhry S, Bagga A, Hari P, et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis. 2009; 53(5): 760–769.
  74. de Mello VR, Rodrigues MT, Mastrocinque TH, et al. Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome. Pediatr Nephrol. 2010; 25(3): 453–460.
  75. Gellermann J, Ehrich JHH, Querfeld U. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrol Dial Transplant. 2012; 27(5): 1970–1978.
  76. Prytuła A, Iijima K, Kamei K, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010; 25(3): 461–468.
  77. Tarshish P, Tobin JN, Bernstein J, et al. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1996; 10(5): 590–593.
  78. Elhence R, Gulati S, Kher V, et al. Intravenous pulse cyclophosphamide--a new regime for steroid-resistant minimal change nephrotic syndrome. Pediatr Nephrol. 1994; 8(1): 1–3.
  79. Lombel RM, Gipson DS, Hodson EM, et al. Kidney Disease: Improving Global Outcomes, Kidney Disease: Improving Global Outcomes. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr Nephrol. 2013; 28(3): 409–414.
  80. Tarshish P, Tobin JN, Bernstein J, et al. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1996; 10(5): 590–593.
  81. Jellouli M, Charfi R, Maalej B, et al. Rituximab in the management of pediatric steroid-resistant nephrotic syndrome: A systematic review. J Pediatr. 2018; 197: 191–197.e1.
  82. Hackl Á, Cseprekál O, Gessner M, et al. Mycophenolate mofetil therapy in children with idiopathic nephrotic syndrome: Does therapeutic drug monitoring make a difference? Ther Drug Monit. 2016; 38(2): 274–279.
  83. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis, Kidney Int. Suppl. ; 2: 153–176.
  84. Trautmann A, Vivarelli M, Samuel S, et al. International Pediatric Nephrology Association. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020; 35(8): 1529–1561.
  85. Wyszyńska T, Litwin M, Książek J, Borowski A, Jarmoliński T. Zespół nerczycowy [Nephrotic syndrome]. [In:] Sieniawska M., (Eds). Nefrologia dziecięca, t. I. Ośrodek Informacji Naukowej „Polfa” Sp. z o.o. In: Wyszyńska T, Litwin M, Książek J, Borowski A, Jarmoliński T. ed. Nefrologia dziecięca, t. I. Ośrodek Informacji Naukowej „Polfa” Sp. z o.o., Warszawa 2003.
  86. Grenda R, Pańczyk-Tomaszewska M, Ziółkowska H. Choroby kłębuszków nerkowych [Renal glomerular diseases]. In: Kawalec W, Grenda R, Kulus M. ed. Pediatria, t. I. PZWL, Warszawa 2008.
  87. Cadnapaphornchai MA, Tkachenko O, Shchekochikhin D, et al. The nephrotic syndrome: pathogenesis and treatment of edema formation and secondary complications. Pediatr Nephrol. 2014; 29(7): 1159–1167.
  88. Bockenhauer D. Over- or underfill: not all nephrotic states are created equal. Pediatr Nephrol. 2013; 28(8): 1153–1156.
  89. Ellis D. Pathophysiology, evaluation, and management of edema in childhood nephrotic syndrome. Front Pediatr. 2015; 3: 111.
  90. Kallash M, Mahan JD. Mechanisms and management of edema in pediatric nephrotic syndrome. Pediatr Nephrol. 2021; 36(7): 1719–1730.
  91. Kitsios GD, Mascari P, Ettunsi R, et al. Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a meta-analysis. J Crit Care. 2014; 29(2): 253–259.
  92. Pasini A, Benetti E, Conti G, et al. The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse. Ital J Pediatr. 2017; 43(1): 41.
  93. Keenswijk W, Ilias MI, Raes A, et al. Urinary potassium to urinary potassium plus sodium ratio can accurately identify hypovolemia in nephrotic syndrome: a provisional study. Eur J Pediatr. 2018; 177(1): 79–84.
  94. Kerlin BA, Blatt NB, Fuh B, et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr. 2009; 155(1): 105–10, 110.e1.
  95. Bauman M, Massicotte MP, Yiu V. Disordered hemostasis and renal disorders. In: Geary DF, Schaefe F. ed. Comprehensive pediatric nephrology. Mosby 2008: 385–394.
  96. KDIGO General principles in the management of glomerular disease. Kidney Int. Suppl. 2012; 2: 156–162.
  97. Zaffanello M, Franchini M. Thromboembolism in childhood nephrotic syndrome: a rare but serious complication. Hematology. 2007; 12(1): 69–73.
  98. Ziółkowska H. Zespół nerczycowy. Pediatr Dypl. 2013; 17: 17–28.
  99. Lilova MI, Velkovski IG, Topalov IB. Thromboembolic complications in children with nephrotic syndrome in Bulgaria (1974-1996). Pediatr Nephrol. 2000; 15(1-2): 74–78.
  100. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol. 2007; 18(8): 2221–2225.
  101. Grenda R, Ziółkowska H. Choroby układu moczowego. In: Kawalec W, Grenda R, Ziółkowska H. ed. Pediatria. PZWL, Warszawa 2013: 657–740.
  102. Park SeJ, Shin JIl. Complications of nephrotic syndrome. Korean J Pediatr. 2011; 54(8): 322–328.
  103. Yang GF, Schoepf UJ, Zhu H, et al. Thromboembolic complications in nephrotic syndrome: imaging spectrum. Acta Radiol. 2012; 53(10): 1186–1194.
  104. Kerlin BA, Haworth K, Smoyer WE. Venous thromboembolism in pediatric nephrotic syndrome. Pediatr Nephrol. 2014; 29(6): 989–997.
  105. Suri D, Ahluwalia J, Saxena AK, et al. Thromboembolic complications in childhood nephrotic syndrome: a clinical profile. Clin Exp Nephrol. 2014; 18(5): 803–813.
  106. Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e737S–e801S.
  107. Wright JM, Watts RG. Venous thromboembolism in pediatric patients: epidemiologic data from a pediatric tertiary care center in Alabama. J Pediatr Hematol Oncol. 2011; 33(4): 261–264.
  108. Pasini A, Benetti E, Conti G, et al. The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse. Ital J Pediatr. 2017; 43(1): 41.
  109. Carpenter SL, Goldman J, Sherman AK, et al. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatr Nephrol. 2019; 34(2): 261–267.
  110. Prescott WA, Streetman DaD, Streetman DS. The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome. Ann Pharmacother. 2004; 38(12): 2105–2114.
  111. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003; 362(9384): 629–639.
  112. Saland JM, Ginsberg H, Fisher EA. Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. Curr Opin Pediatr. 2002; 14(2): 197–204.
  113. Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. Pediatrics. 2009; 124(2): 747–757.
  114. Avis HJ, Hutten BA, Gagné C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010; 55(11): 1121–1126.
  115. de Jongh S, Ose L, Szamosi T, et al. Simvastatin in Children Study Group. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002; 106(17): 2231–2237.
  116. Knipscheer HC, Boelen CC, Kastelein JJ, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res. 1996; 39(5): 867–871.
  117. McCrindle BW, Helden E, Cullen-Dean G, et al. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res. 2002; 51(6): 715–721.
  118. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003; 143(1): 74–80.
  119. Stein EA, Illingworth DR, Kwiterovich PO, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 1999; 281(2): 137–144.
  120. Chapter 4: Pharmacological cholesterol-lowering treatment in children. Kidney Int Suppl (2011). 2013; 3(3): 282–283.
  121. Dogra GK, Watts GF, Herrmann S, et al. Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int. 2002; 62(2): 550–557.
  122. Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: knowledge base, limitations, and future directions. Pediatrics. 2007; 119(2): 370–380.
  123. Noone D, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. The Lancet. 2018; 392(10141): 61–74.
  124. Banerjee S, Basu S, Sengupta J. Vitamin D in nephrotic syndrome remission: a case-control study. Pediatr Nephrol. 2013; 28(10): 1983–1989.
  125. Weng FL, Shults J, Herskovitz RM, et al. Vitamin D insufficiency in steroid-sensitive nephrotic syndrome in remission. Pediatr Nephrol. 2005; 20(1): 56–63.
  126. Mittal SK, Dash SC, Tiwari SC, et al. Bone histology in patients with nephrotic syndrome and normal renal function. Kidney Int. 1999; 55(5): 1912–1919.
  127. Freundlich M, Jofe M, Goodman WG, et al. Bone histology in steroid-treated children with non-azotemic nephrotic syndrome. Pediatr Nephrol. 2004; 19(4): 400–407.
  128. Gulati S, Godbole M, Singh U, et al. Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease? American Journal of Kidney Diseases. 2003; 41(6): 1163–1169.
  129. Choudhary S, Agarwal I, Seshadri MS. Calcium and vitamin D for osteoprotection in children with new-onset nephrotic syndrome treated with steroids: a prospective, randomized, controlled, interventional study. Pediatr Nephrol. 2014; 29(6): 1025–1032.
  130. Banerjee S, Basu S, Sen A, et al. The effect of vitamin D and calcium supplementation in pediatric steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2017; 32(11): 2063–2070.
  131. Yadav VK, Sharma S, Debata PK, et al. Change in bone mineral density and role of vitamin D and calcium supplementation during treatment of first episode nephrotic syndrome. J Clin Diagn Res. 2017; 11(9): SC18–SC21.
  132. Selewski DT, Chen A, Shatat IF, et al. Vitamin D in incident nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol. 2016; 31(3): 465–472.
  133. Emma F, Sesto A, Rizzoni G. Long-term linear growth of children with severe steroid-responsive nephrotic syndrome. Pediatr Nephrol. 2003; 18(8): 783–788.
  134. Donatti TL, Koch VH, Fujimura MD, et al. Growth in steroid-responsive nephrotic syndrome: a study of 85 pediatric patients. Pediatr Nephrol. 2003; 18(8): 789–795.
  135. Elzouki AY, Jaiswal OP. Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood. Effect on remission, statural growth, obesity, and infection rate. Clin Pediatr (Phila). 1988; 27(8): 387–392.
  136. Jabs K, Sullivan EK, Avner ED, et al. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation. 1996; 61(1): 31–36.
  137. Chapter 3: Steroid-sensitive nephrotic syndrome in children. Kidney Int Suppl (2011). 2012; 2(2): 163–171.
  138. Czajka H, Wysocki J. Szczepienia w profilaktyce chorób zakaźnych. Vademecum. Helpmed, Kraków 2010.
  139. Rubik J. Szczepienia u pacjentów nefrologicznych — kiedy i jakie szczepionki są konieczne? Klinika Pediatryczna. 2008; 16: 350–353.
  140. Komunikat Głównego Inspektora Sanitarnego z dnia 31 października 2017 r. w sprawie Programu Szczepień Ochronnych na rok 2018. Dziennik Urzędowy Ministra Zdrowia, poz. 108 z 31 października 2017 r.
  141. Immunisation guideline for children with chronic kidney disease. Renal Unit Royal Hospital for Sick Children Yorkhill Division, Nov. 2011;. https://www.clinicalguidelines.scot.nhs.uk/nhsggc-paediatric-clinical-guidelines/nhsggc-guidelines/kidney-diseases/immunisation-guideline-for-children-with-chronic-kidney-disease/.
  142. Nuorti JP, Whitney CG. Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010; 59(RR-11): 1–18.
  143. https://publications.aap.org/redbook.
  144. http://www.cdc.gov/vaccines/schedules/hcp/index.html.
  145. Alpay H, Yildiz N, Onar A, et al. Varicella vaccination in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2002; 17(3): 181–183.
  146. Poyrazoğlu HM, Düşünsel R, Gündüz Z, et al. Antibody response to influenza A vaccination in children with nephrotic syndrome. Pediatr Nephrol. 2004; 19(1): 57–60.
  147. Ulinski T, Leroy S, Dubrel M, et al. High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone. Pediatr Nephrol. 2008; 23(7): 1107–1113.
  148. Immunisation of the immunocompromised child. Best Practice Statement. February 2002. Royal College of Paediatrics and Child Healt. http://rcpch.adlibhosting.com/files/Immunisation%20of%20the%20Immunocompromised%20Child%C2%A02002-02.pdf..
  149. Janus N, Vacher LV, Karie S, et al. Vaccination and chronic kidney disease. Nephrol Dial Transplant. 2008; 23(3): 800–807.
  150. Kamei K, Miyairi I, Ishikura K, et al. Prospective study of live attenuated vaccines for patients with nephrotic syndrome receiving immunosuppressive agents. J Pediatr. 2018; 196: 217–222.e1.



Renal Disease and Transplantation Forum